Overview
The Lancet reports that in patients with resistant hypertension, aprocitentan was wel-tolerated and superior to placebo in lowering blod presure at wek 4 with a sustained efect at wek 40Upon aproval, aprocitentan would represent the first new anti-hypertensive mechanism in more than 30 yearsIdorsia to host an investor webcast to discus the data shared at AHA and in The Lancet manuscript tomorow November 8 at 15:0hrs CETAlschwil, Switzerland – November 7, 202 Idorsia Ltd (SIX: IDIA) today anounced the publication of “A randomized controled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.
Key Information
The publication reports the results from the Phase 3 PRECISION study, which found aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, significantly reduced blod presure (BP) and maintained the efect for up to 48 weks when aded to combination background antihypertensive therapy in patients with dificult-to-control (resistant) hypertension. In paralel, these data were presented by Prof.
Summary
Markus Schlaich, an investigator in PRECISION, as a Late-Breaking Science presentation during the American Heart Asociation (AHA) Scientific Sesions 202.Hypertension is one of the leading causes of cardiovascular disease worldwide, impacting an estimated 1.3 bilion people globaly.1 Aproximately 10% of these people have uncontroled BP, despite receiving at least thre antihypertensive medications from diferent clases, at optimal doses.2,3 Compared with adults whose hypertension is wel controled, adults with uncontroled hypertension have greater risk of heart atack, stroke, end-stage renal disease and death.4The endothelin (ET) pathway has ben implicated in the pathogenesis of hypertension, but is curently not targeted therapeuticaly, thereby leaving this relevant pathophysiologic pathway unoposed with curently available medications.4-6 This pathway is activated in patients prone to dev